Ebola virus disease (EVD), also known as Ebola hemorrhagic fever (EHF), results from Ebola virus and three other closely related viruses in the genes (group of related viruses) of ebola virus. Initial symptoms of this disease include sore throat, headaches, fever and muscles pain. It causes hemorrhagic fever that leads to internal or external bleeding. EVD is widely prevalent in Central and Western Africa, and near tropical rainforests. Due to high mortality rate and unavailability of effective treatments, the pharmaceutical companies have big opportunities to explore. Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical are some of the leading companies focusing on research activities to develop efficacious medicine for EVD. Additionally, the governments in the developed countries have also taken formidable steps to support the research activities for the development of EVD therapeutics by providing funding and floating favorable policies. As an example, Tekmira Pharmaceuticals has received fast-track designation from U.S. food and drug administration for their anti-ebola therapeutic TKM-ebola. In 2012, Sarepta Therapeutics had also received fast track designation for AVI-7537, a lead drug candidate for EVD. Both these companies are developing their anti-ebola products under the contract of the U.S. department of defense (DoD).
Ebola therapeutics and vaccines market is segmented on the basis of geography into North America, Europe, Asia-pacific and LAMEA. EVD is rampant in LAMEA regions, specifically in African countries. This is a positive sign for pharmaceutical companies, portraying a highly lucrative market in the future. Earlier, US government did not have any regulations for EVD therapeutics due to negligible incidences of this disease in developed economies. However, preference of African people to migrate to developed economies rather than developing economies has cautioned the governments in the developed economies, leading to formulate regulations in order to curb the spread of this disease.
This report offers the following benefits in particular:
KEY MARKET SEGMENTS
Ebola therapeutics and vaccines market is segmented on the basis of geography.
SIMILAR MARKET STUDIES
Notes: Sales, means the sales volume of Medical video recorders Revenue, means the sales value of Medical video recorders This report studies sales (consumption) of Medical video recorders in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and ...
December 2016 | $3900 | View Details >>
The Global and Chinese Doxofylline Industry, 2010-2020 Market Research Report is a professional and in-depth study on the current state of the global Doxofylline industry with a focus on the Chinese market. The report provides key statistics on the market status of the Doxofylline manufacturers and is a valuable source ...
November 2015 | $2800 | View Details >>
In this report, the global Protein Biochip market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (volume), ...
March 2017 | $4000 | View Details >>
Summary ImmunoCellular Therapeutics, Ltd. (IMCU) is a clinical-stage biotechnology company which develops immune-based therapies for the treatment of various cancers. The product pipeline of the company includes active immunotherapies and patented monoclonal antibodies. IMCU’s immunotherapies product pipeline comprises ICT-107, ICT-140 and ICT-121. ICT-107, the lead product candidate of the company is ...
August 2016 | $250 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research